Medicine is changing, and the Teladoc Health stock (NASDAQ: TDOC) is at the cusp of the industry transformation. Teladoc Health allows users to access expert medical advice, organise medical records, manage health risks, and enter virtual mental health appointments at the touch of a button. Teladoc Health recently acquired biotech giant Livongo (NASDAQ: LVNGO).… Read more
Bausch Health rises 25% on bad earnings – is this pump a trap for retail investors?
Bausch Health’s (NASDAQ: BHC) pre-market rally is causing the ears of investors to prick up as the word gets out. While the sentiment appears to be positive at the moment investors could be in for a rollercoaster at the bell. Considering the pre-market is a usually a façade for the trading day, many investors are skeptical as to whether the rally will hold up.… Read more
Sorrento Therapeutics soars 10% from Jim Cramer’s bullish outlook – should investors avoid shorting SRNE?
Sorento Therapeutics (NASDAQ: SRNE) is causing Wall Street to divide. Some bears are adamant that Sorrento will become a COVID-19 stock that will fade in a few months. Whereas the bulls are aggressively buying up SRNE shares as they believe the biotech has not even come close to its true value.… Read more
Here’s how much a $10,000 investment in this COVID-19 vaccine company is worth now
The COVID-19 vaccine industry has seen immense investor backing with popular US listed companies such as Moderna, Pfizer and Vaxart multiplying their pre-COVID value upwards of 500%-1,000%. However, Novavax, Inc. (NASDAQ: NVAX) has surpassed it’s rivals in stock value growth, currently priced at $143.10. An investment of $10,000 in NVAX after the initial COVID-19 vaccine announcement in March, would now be worth over $207,000.… Read more
BNGO rises 100% off COVID-19 DNA research – here’s what you need to know.
Binano Genomics (NASDAQ: BNGO) catapulted itself onto the COVID-19 stage this week, which naturally saw investors flood the market. The area that BNGO is targeting is the COVID research field. However, for most investors, the scientific jargon can make the task of understanding the company, let alone investing, extremely difficult.… Read more
U.S. Health officials order 100 million doses of Pfizer’s vaccine – does YIG see value?
Along with the NASDAQ, vaccine stocks have wrenched back the stock market remote control as the pandemic worsens. Today, it was Pfizer (NYSE: PFE) who stole the spotlight. U.S health officials have agreed to pay $1.95 billion for 100 million doses of Pfizer and BioNTech coronavirus vaccine. … Read more
Actinium Pharmaceuticals hits 150% gain over 2 months – here’s everything you need to know
Actinium Pharmaceuticals (NYSE:ATNM) has caught the attention of investors as the stock continues its path of strong bullish momentum. ATNM is likely to open at $0.56 according to pre-market movements, marking a 211% gain over the past 2 months. The Bio-Pharma works on the development of commercial therapies for bone marrow transplant and other adoptive cell therapies.… Read more
Astra Zeneca posts positive Phase I COVID-19 trial data yet investors sell – does YIG see potential?
Astra Zeneca (NYSE: AZN) had investors on the edge of their seats this morning in anticipation of COVID-19 data. AZN put investors at ease after their COVID-19 Phase I trial saw a positive immune response in patients. Most investors expected the stock to rocket off such news.… Read more
Moderna COVID-19 vaccine success – here’s everything you need to know.
Moderna (NASDAQ:MRNA) alongside the US National Institutes of Health have made a historic breakthrough in the race for a viable COVID-19 vaccine. MRNA’s results showed all 45 patients from the Phase 1 trial saw an induced anti-body production. This anti-body production simply put helps bolster the individuals immune response to the virus.… Read more
Vaxart is up 60% on vaccine speculation – does YIG see potential?
Vaxart (NASDAQ:VXRT), like most COVID-19 stocks, is receiving a re-injection of investor confidence as the virus rages on. However, Vaxart is fairly new to the COVID-19 race, as they have not started any human trials yet. Some investors are straying away from Vaxart because of their late arrival and unlikelihood of creating a viable vaccine before other frontrunners.… Read more
NVAX receives $1.6 billion from Trump’s Operation Warp Speed, causing Novavax to cross $100 – should you invest?
Novavax (NASDAQ: NVAX) inched closer to the COVID-19 vaccine finish line after receiving $1.6 billion in government funding today. The bulls are now rally in large numbers behind the COVID-19 biotech. Especially in light of today’s announcement. However, many investors wonder how long it will be until the NVAX bulls have to rest?… Read more
INO falls 18% on positive phase I COVID-19 trials – where to next for investors?
Inovio Pharmaceuticals (NASDAQ: INO), last week’s COVID-19 spectacle has now capitulated investors into no mans land after falling after positive Phase I data. It seems strange right, investors were backing INO with the expectation of positive phase I trials. INO fulfilled the expectation yet the bears decided to take the biotech to the woodshed.… Read more
Vaxart rises 300% after its COVID-19 vaccine joins Trump’s Operation Warp Speed – is now the time to invest?
Vaxart Incorporated (NASDAQ: VXRT), wrenched the spotlight off COVID-19 frontrunners after its oral vaccine received funding from “Operation Warp Speed,” Trump’s accelerated vaccine program. The funding is causing investors to empty their wallets into the stock. The stock did skyrocket to the moon initially. However, now VXRT is following a downward spiral.… Read more
ESKO skyrockets 170% after FDA approves its brain injury device – is Esko Bionics worth the investment?
Esko bionics (NASDAQ: ESKO) is causing the eyes of investors light up with money symbols after the FDA gave the green light yesterday. While volatility is high, the future is showing signs of upward growth. However, the bears could ignite a sell-off at any point. Making many investors wonder, is Esko Bionics a good investment?… Read more
SRNE surges 20% off COVID-19 lawsuit – has news been leaked?
Sorrento Therapeutics’ (NASDAQ: SRNE) saying they have a COVID-19 treatment that offers a 100% protection, before conducting trials, was an incredibly bold statement. SRNE’s optimistic announcement not only lit the investment world alight but also pushed them into the legal spotlight. It is the possible lawsuit charges that caused the bears to multiply.… Read more
INO’s COVID-19 vaccine receives $71 million in government funding – how high can the INO stock go?
The COVID-19 vaccine market was fading as economies began to recover. However, the insurgence of new coronavirus cases and deaths is causing investors to gravitate towards COVID-19 vaccine frontrunners Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), and Inovio Pharmaceuticals (NASDAQ: INO). It makes logical sense that investors rally behind the vaccine companies.… Read more
BREAKING: Glenmark’s COVID-19 drug gets market approval – causing an enormous rally in India today.
Glenmark Pharmaceuticals (XNSE: GLENMARK) COVID-19 drug, FabiFlu, is acting as a magnet to the eyes and wallets of investors. Considering India has 426,910 coronavirus cases and counting, it makes sense that many eyeballs are watching the Mumbai based biotech. Indian COVID-19 cases are forecasted to grow before they flatten.… Read more
Enochian Biosciences Skyrockets 240% pre-market on potential HIV cure
Enochian Biosciences (NASDAQ:ENOB) stock price has set for the stars this morning – with pre markets predicting the stock to open 240% higher. The significant increase has come off the back of a press release confirming an FDA meeting which successfully “aligned” with Enochian’s strategy for a HIV cure.… Read more
Gilead produces mixed COVID-19 trial results – investors now look to Mesoblast.
Biotechs universally share one mission. The industry aims to prevent or cure diseases to sustain a higher life expectancy. If a biotech successfully achieves its mission, humankind, the patients suffering, and investors all experience euphoria. However, if a biotech fails to develop a viable drug then the nightmarish scenario of people suffering continues.… Read more
ADAP soars 150% on positive Phase 1 cancer trials – is a sell-off inevitable?
Why did the ADAP surge this week?
Adaptimmune Therapeutics PLC (Nasdaq: ADAP) skyrocketed 128% on Friday. Investors rallied behind ADAP because of their positive phase 1 cancer trial. ADAP’s synovial sarcoma cancer candidate (ADP-A2M4) reported a 50% response rate in patients suffering from lung, head, and neck cancers.… Read more